Streptomycin Residues in Cattle Tissues; Withdrawal of Compliance Policy Guide, 38650-38651 [E6-10671]
Download as PDF
38650
Federal Register / Vol. 71, No. 130 / Friday, July 7, 2006 / Notices
Dated: June 28, 2006.
Michelle Shortt,
Director, Regulations Development Group,
Office of Strategic Operations and Regulatory
Affairs.
[FR Doc. E6–10587 Filed 7–6–06; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
cprice-sewell on PROD1PC66 with NOTICES
Administration for Developmental
Disabilities
Award To: Oregon Health & Science
University, Child Development &
Rehabilitation Center.
Purpose: To supplement a grant
award for support of ‘‘Making It Real:
Participatory Action Research (PAR) for
University Centers for Excellence in
Developmental Disabilities (UCEDDs)’’.
Amount of Award: $65,000 for one
year.
Project Period: 7/1/2006—6/30/2007.
Justification for Exception to
Competition: After consulting with
relevant, informed sources, including
individuals with developmental
disabilities and their families, the
Administration for Developmental
Disabilities (ADD) determined that it
was beneficial to continue funding the
Oregon Health & Science University,
Child Development & Rehabilitation
Center project to strengthen and expand
the inclusion of people with
developmental disabilities and their
family members in participatory action
research projects at University Centers
for Excellence in Developmental
Disabilities (UCEDDs).
The Oregon Institute on Disability &
Development, the Oregon Health and
Science University, Child Development
and Rehabilitation Center will receive a
sole source program expansion
supplemental grant for ‘‘Making It Real:
Participatory Action Research (PAR) for
UCEDDs,’’ a training initiative on the
critical and emerging needs of
individuals with developmental
disabilities and their families. Through
the project, a tool kit is being created
that will include tested educational
modules on participatory action
research. Through the creation of the
toolkit, every UCEDD will be able to
access resources that will enhance and
increase PAR and support initiatives
that are most meaningful to people with
developmental disabilities and their
families. It will also be available to
individuals with developmental
disabilities, family members, advocacy
groups, and other interested
VerDate Aug<31>2005
15:46 Jul 06, 2006
Jkt 208001
organizations. By continuing funding of
this project, additional resources will be
developed, including materials in
Spanish. In addition, the expansion
supplement will allow for more time
and resources to enhance training and
dissemination efforts.
The Administration for Children and
Families intends to supplement the
current grant by $65,000. The grantee
will continue to provide a 25 percent
match.
FOR FURTHER INFORMATION CONTACT:
Jennifer G. Johnson, Ed.D., Program
Specialist, Administration on
Developmental Disabilities, 200
Independence Avenue, SW., Room 405–
D, Washington, DC 20201. Telephone:
202/690–5982 (v); 202/205–8037 (f). Email: jennifer.johnson@acf.hhs.gov.
Dated: June 21, 2006.
Patricia A. Morrissey,
Commissioner, Administration for
Developmental Disabilities.
[FR Doc. E6–10578 Filed 7–6–06; 8:45 am]
BILLING CODE 4184–01–P
was signed into law on October 22,
1994. AMDUCA allows veterinarians to
prescribe extralabel uses of approved
animal drugs and approved human
drugs for animals under certain
conditions. An extralabel use must be
by or on the order of a licensed
veterinarian within the context of a
veterinarian-client-patient relationship
and must be in conformance with the
implementing regulations published in
part 530 (21 CFR part 530). A list of
drugs specifically prohibited from
extralabel use in animals is in § 530.41.
With the enactment of AMDUCA and
the issuance of implementing
regulations, FDA is withdrawing CPG
7125.35 because it is obsolete. On
September 24, 1998, a CPG section
615.100 entitled ‘‘Extralabel Use of New
Animal Drugs in Food-Producing
Animals (CPG 7125.06)’’ was withdrawn
for the same reason (63 FR 51074).
Dated: June 20, 2006.
Margaret O’K. Glavin,
Associate Commissioner for Regulatory
Affairs.
[FR Doc. E6–10672 Filed 7–6–06; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4160–01–S
Food and Drug Administration
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Docket No. 1990D–0428]
Human-Labeled Drugs Distributed and
Used in Animal Medicine; Withdrawal
of Compliance Policy Guide
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; withdrawal.
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
[Docket No. 2006D–0214]
Streptomycin Residues in Cattle
Tissues; Withdrawal of Compliance
Policy Guide
AGENCY:
The Food and Drug
Administration (FDA) is announcing the
withdrawal of a compliance policy
guide (CPG) that was issued on March
19, 1991.
DATES: July 7, 2006.
FOR FURTHER INFORMATION CONTACT:
Diane D. Jeang, Division of Compliance
Policy (HFC–230), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 240–632–6833.
SUPPLEMENTARY INFORMATION: In a notice
published in the Federal Register of
July 30, 1992 (57 FR 33729), FDA
announced the availability of a revised
CPG 7125.35 entitled ‘‘Human-Labeled
Drugs Distributed and Used in Animal
Medicine.’’ The CPG is being withdrawn
because it is obsolete. This CPG
explained how FDA would exercise its
enforcement discretion with respect to
the distribution and use of humanlabeled drug products for use in
animals.
The Animal Medicinal Drug Use
Clarification Act of 1994 (AMDUCA)
SUMMARY:
Food and Drug Administration
Food and Drug Administration,
HHS.
ACTION:
Notice; withdrawal.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
withdrawal of the compliance policy
guide (CPG) entitled ‘‘Sec. 616.100
Streptomycin Residues in Cattle Tissues
(CPG 7125.22).’’ This CPG is obsolete.
DATES: The withdrawal is effective July
7, 2006.
FOR FURTHER INFORMATION CONTACT:
Diane D. Jeang, Division ofCompliance
Policy (HFC–230), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 240–632–6833.
SUPPLEMENTARY INFORMATION: FDA
issued the CGP entitled ‘‘Sec. 616.100
Streptomycin Residues in Cattle Tissues
(CPG 7125.22)’’ on October 1, 1980. The
CPG was issued because there were no
published tolerances for residues of
streptomycin in cattle tissue and the
available data supported an action level
of 2 part per million (ppm)
streptomycin/dihydrostreptomycin
E:\FR\FM\07JYN1.SGM
07JYN1
38651
Federal Register / Vol. 71, No. 130 / Friday, July 7, 2006 / Notices
residues in cattle kidney tissue. The
U.S. Department of Agriculture, Food
Safety Quality Service (now known as
the Food Safety Inspection Service)
agreed to report any detectable residues
in other edible tissue and to report to
FDA only those cattle kidney tissue
reports where the streptomycin residue
was 2 ppm or more.
Since issuing this CPG, FDA has
established tolerances for
dihydrostreptomycin (59 FR 41976,
August 16, 1994) and streptomycin (58
FR 47210, September 8, 1993).
Tolerances are established for residues
of dihydrostreptomycin in uncooked,
edible tissues of cattle and swine of 2.0
ppm in kidney and 0.5 ppm in other
tissues, and 0.125 ppm in milk. (See 21
CFR 556.200.) Tolerances are
established for residues of streptomycin
in uncooked, edible tissues of chickens,
swine, and calves of 2.0 ppm in kidney,
and 0.5 ppm in other tissues. (See 21
CFR 556.610.)
FDA is withdrawing CPG 7125.22, in
its entirety, to eliminate obsolete
compliance policy.
Dated: June 20, 2006.
Margaret O’K. Glavin,
Associate Commissioner for Regulatory
Affairs.
[FR Doc. E6–10671 Filed 7–6–06; 8:45 am]
Proposed Project: The Health Education
Assistance Loan (HEAL) Program:
Forms (OMB No. 0915–0034 Extension)
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Health Resources
and Services Administration (HRSA)
publishes abstracts of information
collection requests under review by the
Office of Management and Budget
(OMB), in compliance with the
Paperwork Reduction Act of 1995 (44
U.S.C. chapter 35). To request a copy of
the clearance requests submitted to
OMB for review, call the HRSA Reports
Clearance Office on (301) 443–1129.
The following request has been
submitted to the Office of Management
and Budget for review under the
Paperwork Reduction Act of 1995:
Responses
per
respondent
Number of
respondents
Collection activity
The HEAL program provides federally
insured loans to assure the availability
of funds for loans to eligible students to
pay for their education costs. In order to
administer and monitor the HEAL
program, the following forms are
utilized: The Application for Contract of
Federal Loan Insurance form (used by
lenders to make application to the
HEAL insurance program and formerly
entitled Lenders Application for
Contract of Federal Loan Insurance
form); the Borrower’s Deferment
Request form (used by borrowers to
request deferments on HEAL loans and
used by lenders to determine borrower’s
eligibility for deferment); the Borrower
Loan Status update electronic
submission (submitted monthly by
lenders to the Secretary on the status of
each loan); and the Loan Purchase/
Consolidation electronic submission
(submitted by lenders to the Secretary to
report sales, and purchases of HEAL
loans).
The estimates of burden for the forms
are as follows:
Total
responses
Hours per
response
Total burden
hours
Application for Contract of Federal Loan Insurance ..............
Borrower’s Deferment Request:
Borrowers ........................................................................
Employers .......................................................................
Borrower Loan Status Update ................................................
Loan Purchase/Consolidation ................................................
17
1
17
8 min ...........
3
436
261
8
17
1
1.669
18
248
436
436
144
4,216
10 min .........
5 min ...........
10 min .........
4 min ...........
73
36
24
281
Total ................................................................................
739
........................
5,249
.....................
417
Written comments and
recommendations concerning the
proposed information collection should
be sent within 30 days of this notice to:
John Kraemer, Human Resources and
Housing Branch, Office of Management
and Budget, New Executive Office
Building, Room 10235, Washington, DC
20503.
cprice-sewell on PROD1PC66 with NOTICES
Dated: June 29, 2006.
Cheryl R. Dammons,
Director, Division of Policy Review and
Coordination.
[FR Doc. E6–10591 Filed 7–6–06; 8:45 am]
BILLING CODE 4165–15–P
VerDate Aug<31>2005
17:24 Jul 06, 2006
Jkt 208001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
Advisory Committee to the Director,
National Institutes of Health (NIH).
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
and personal information concerning
individuals associated witht he grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal property.
Name of Committee: Advisory Committee
to the Director, NIH.
Date: August 17, 2006.
Time: 2 p.m. to 3 p.m.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Room 5B64,
Bethesda, MD 20892.
Agenda: To review and evaluate grant
applications (Telephone Conference Call).
Contact Person: Shelly Pollard, ACD
Coordinator, National Institutes of Health,
9000 Rockville Pike, Building 31, Room
5B64, Bethesda, MD 20892, (301) 496–0959,
pollards@mail.nih.gov.
E:\FR\FM\07JYN1.SGM
07JYN1
Agencies
[Federal Register Volume 71, Number 130 (Friday, July 7, 2006)]
[Notices]
[Pages 38650-38651]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-10671]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006D-0214]
Streptomycin Residues in Cattle Tissues; Withdrawal of Compliance
Policy Guide
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; withdrawal.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
withdrawal of the compliance policy guide (CPG) entitled ``Sec. 616.100
Streptomycin Residues in Cattle Tissues (CPG 7125.22).'' This CPG is
obsolete.
DATES: The withdrawal is effective July 7, 2006.
FOR FURTHER INFORMATION CONTACT: Diane D. Jeang, Division ofCompliance
Policy (HFC-230), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 240-632-6833.
SUPPLEMENTARY INFORMATION: FDA issued the CGP entitled ``Sec. 616.100
Streptomycin Residues in Cattle Tissues (CPG 7125.22)'' on October 1,
1980. The CPG was issued because there were no published tolerances for
residues of streptomycin in cattle tissue and the available data
supported an action level of 2 part per million (ppm) streptomycin/
dihydrostreptomycin
[[Page 38651]]
residues in cattle kidney tissue. The U.S. Department of Agriculture,
Food Safety Quality Service (now known as the Food Safety Inspection
Service) agreed to report any detectable residues in other edible
tissue and to report to FDA only those cattle kidney tissue reports
where the streptomycin residue was 2 ppm or more.
Since issuing this CPG, FDA has established tolerances for
dihydrostreptomycin (59 FR 41976, August 16, 1994) and streptomycin (58
FR 47210, September 8, 1993). Tolerances are established for residues
of dihydrostreptomycin in uncooked, edible tissues of cattle and swine
of 2.0 ppm in kidney and 0.5 ppm in other tissues, and 0.125 ppm in
milk. (See 21 CFR 556.200.) Tolerances are established for residues of
streptomycin in uncooked, edible tissues of chickens, swine, and calves
of 2.0 ppm in kidney, and 0.5 ppm in other tissues. (See 21 CFR
556.610.)
FDA is withdrawing CPG 7125.22, in its entirety, to eliminate
obsolete compliance policy.
Dated: June 20, 2006.
Margaret O'K. Glavin,
Associate Commissioner for Regulatory Affairs.
[FR Doc. E6-10671 Filed 7-6-06; 8:45 am]
BILLING CODE 4160-01-S